Bristol-Myers Squibb Company
I · Análisis con IA
En breve
Bristol-Myers Squibb discovers, develops, manufactures, and sells prescription medicines worldwide, focusing on cancer treatments (Opdivo, Yervoy, Breyanzi), immune system drugs (Orencia, Zeposia), blood disorder treatments (Reblozyl, Revlimid), and cardiovascular medicines (Eliquis) [Yahoo Finance]. The company sells through wholesalers, specialty pharmacies, hospitals, and government agencies across global markets [Yahoo Finance].
Bristol-Myers Squibb is a large pharmaceutical company that develops and sells drugs for cancer, immune diseases, heart conditions, and neurological disorders [Yahoo Finance]. The company generates $48.2B in annual revenue, maintains a $119B market cap, and is financially healthy with strong cash flow [Yahoo Finance]. Recent news highlights aggressive AI partnerships with Anthropic and Tempus AI to accelerate drug discovery, plus a major $1B manufacturing expansion in Houston [Yahoo Finance].
Bristol-Myers Squibb is financially healthy with strong profitability and solid cash generation, though revenue is flat year-over-year [Yahoo Finance].
Puntuación Sentinellis
7.4/10
Financially healthy
Capitalización bursátil
$119.1B
Ingresos (12 meses)
$48.2B
II · Noticias recientes
Qué movió el precio
6 stories · ranked by relevance
- macro2026-05-20
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
Yahoo Finance
- macro2026-05-19
How The Bristol Myers Squibb (BMY) Story Is Shifting Around Pipeline Hopes And Patent Risks
Simply Wall St
- macro2026-05-20
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
Yahoo Finance
- macro2026-05-18
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts
Benzinga
- macro2026-05-19
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks
- macro2026-05-18
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist
Simply Wall St
Premium · gratis con cualquier cuenta
Revenue is flat year-over-year at -0.2%, signaling potential challenges in maintaining growth momentum as key drug patents approach expiration [Yahoo Finance].
Riesgos
4
Oportunidades
6
Señales de alerta
1
Dirección
10
20 hallazgos más en el informe completo — gratis con cualquier cuenta.
Desbloquea el análisis completo de Bristol-Myers Squibb Company
Crea una cuenta gratuita para acceder al informe completo generado con IA, con fuentes citadas en el texto.
- 4 riesgos, 6 oportunidades y 1 señal de alerta — cada uno con su fuente
- Más de 100 métricas financieras con gráficos y comparativas
- Resúmenes completos de noticias con enlaces a las fuentes
- Equipo directivo y remuneración
- Exportación a PDF para leer sin conexión
III · Empresas similares
También te puede interesar
Same sector · Healthcare or comparable health
¿La añades a tu lista?